Depletion of measles virus glycoprotein-specific antibodies from human sera reveals genotype-specific neutralizing antibodies

Journal of General Virology

Volumn 90, Issue 12, 2009, Pages 2982-2989

  de Swart, Rik L ^a   Yüksel, Selma ^a   Langerijs, Carianne N ^a   Muller, Claude P ^b   Osterhaus, Albert D M E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LABORATOIRE NATIONAL DE SANTÉ   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G; MEASLES ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN; VIRUS GLYCOPROTEIN F; VIRUS GLYCOPROTEIN H;

ANTIBODY TITER; ARTICLE; COCULTURE; CONTROLLED STUDY; GENOTYPE; HUMAN; INCUBATION TIME; MEASLES; MEASLES VIRUS; PRIORITY JOURNAL; PROTEIN DEPLETION; VIRUS STRAIN;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; GENOTYPE; HUMANS; IMMUNE SERA; IMMUNOGLOBULIN G; MEASLES; MEASLES VIRUS; TRANSFECTION; VIRAL FUSION PROTEINS; VIRAL PROTEINS;

MEASLES VIRUS;

EID: 70849102602     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.014944-0     Document Type: Article

References (33)

1. Armstrong, M. A., Fraser, K. B. & Shirodaria, P. V. (1979). The sensitivity of measles virus haemolysin to acetone and the preparation of monospecific human anti-haemolysin by absorption. J Gen Virol 44, 541-544.
2. Atabani, S. F., Obeid, O. E., Chargelegue, D., Aaby, P., Whittle, H. & Steward, M. W. (1997). Identification of an immunodominant neutralizing and protective epitope from measles virus fusion protein by using human sera from acute infection. J Virol 71, 7240-7245.
3. Bouche, F. B., Ertl, O. T. & Muller, C. P. (2002). Neutralizing B cell response in measles. Viral Immunol 15, 451-471.
4. Chen, R. T., Markowitz, L. E., Albrecht, P., Stewart, J. A., Mofenson, L. M., Preblud, S. R. & Orenstein, W. A. (1990). Measles antibody: reevaluation of protective titers. J Infect Dis 162, 1036-1042.
5. De Serres, G., Boulianne, N., Meyer, F. & Ward, B. J. (1995). Measles vaccine efficacy during an outbreak in a highly vaccinated population: incremental increase in protection with age at vaccination up to 18 months. Epidemiol Infect 115, 315-323.
6. de Swart, R. L., Vos, H. W., UytdeHaag, F. G. C. M., Osterhaus, A. D. M. E. & van Binnendijk, R. S. (1998). Measles virus fusion protein-and hemagglutinin-transfected cell lines are a sensitive tool for the detection of specific antibodies by a FACS-measured immunofluorescence assay. J Virol Methods 71, 35-44.
7. de Swart, R. L., Yüksel, S. & Osterhaus, A. D. M. E. (2005). Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. J Virol 79, 11547-11551.
8. + lymphocytes and dendritic cells during measles virus infection of macaques. PLoS Pathog 3, e178.
9. El Mubarak, H. S., Van de Bildt, M. W. G., Mustafa, O. A., Vos, H. W., Mukhtar, M. M., Groen, J., El Hassan, A. M., Niesters, H. G. M., Ibrahim, S. A. & other authors (2000). Serological and virological characterization of clinically diagnosed cases of measles in suburban Khartoum. J Clin Microbiol 38, 987-991.
10. Enders, J. F. & Peebles, T. C. (1954). Propagation in tissue cultures of cytopathic agents from patients with measles. Proc Soc Exp Biol Med 86, 277-286.
11. Fayolle, J., Verrier, B., Buckland, R. & Wild, T. F. (1999). Characterization of a natural mutation in an antigenic site on the fusion protein of measles virus that is involved in neutralization. J Virol 73, 787-790.
12. Fine, P. E. & Zell, E. R. (1994). Outbreaks in highly vaccinated populations: implications for studies of vaccine performance. Am J Epidemiol 139, 77-90.
13. Frank, S. A. & Bush, R. M. (2007). Barriers to antigenic escape by pathogens: trade-off between reproductive rate and antigenic mutability. BMC Evol Biol 7, 229.
14. Griffin, D. E. (2007). Measles virus. In Fields Virology, 5th edn, pp. 1551-1585. Edited by D. M. Knipe & P. M. Howley. Philadelphia: Lippincott Williams & Wilkins.
15. Hanses, F., Van Binnendijk, R. S., Ammerlaan, W., Truong, A. T., De Rond, L., Schneider, F. & Muller, C. P. (2000). Genetic variability of measles viruses circulating in the Benelux. Arch Virol 145, 541-551.
16. Itoh, M., Okuno, Y. & Hotta, H. (2002). Comparative analysis of titers of antibody against measles virus in sera of vaccinated and naturally infected Japanese individuals of different age groups. J Clin Microbiol 40, 1733-1738.
17. Johnson, J. P., Demmer-Dieckmann, M., Meo, T., Hadam, M. R. & Riethmuller, G. (1981). Surface antigens of human melanoma cells defined by monoclonal antibodies. I. Biochemical characterization of two antigens found on cell lines and fresh tumors of diverse origin. Eur J Immunol 11, 825-831.
18. Kühne, M., Brown, D. W. G. & Jin, L. (2006). Genetic variability of measles virus in acute and persistent infections. Infect Genet Evol 6, 269-276.
19. Muller, C. P., Huiss, S. & Schneider, F. (1996). Secondary immune responses in parents of children with recent measles. Lancet 348, 1379-1380.
20. Ono, N., Tatsuo, H., Hidaka, Y., Aoki, T., Minagawa, H. & Yanagi, Y. (2001). Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J Virol 75, 4399-4401.
21. Paunio, M., Hedman, K., Davidkin, I., Valle, M., Heinonen, O. P., Leinikki, P., Salmi, A. & Peltola, H. (2000). Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. Epidemiol Infect 124, 263-271.
22. Reyes, M. A., de Borrero, M. F., Roa, J., Bergonzoli, G. & Saravia, N. G. (1987). Measles vaccine failure after documented seroconversion. Pediatr Infect Dis J 6, 848-851.
23. Rota, P. A., Featherstone, D. A. & Bellini, W. J. (2009). Molecular epidemiology of measles virus. Curr Top Microbiol Immunol 330, 129-150.
24. Samb, B., Aaby, P., Whittle, H. C., Seck, A. M. C., Rahman, S., Bennett, J., Markowitz, L. & Simondon, F. (1995). Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Infect Dis J 14, 203-209.
25. Santibanez, S., Niewies k, S., Heider, A., Schneider-Schaulies, J., Berbers, G. A. M., Zimmermann, A., Halenius, A., Wolbert, A., Deitemeier, I. & other authors (2005). Probing neutralizing-antibody responses against emerging measles viruses (MVs): immune selection of MV by H protein-specific antibodies? J Gen Virol 86, 365-374.
26. Sastre, P., Melero, J. A., García-Barreno, B. & Palomo, C. (2005). Comparison of affinity chromatography and adsorption to vaccinia virus recombinant infected cells for depletion of antibodies directed against respiratory syncytial virus glycoproteins present in a human immunoglobulin preparation. J Med Virol 76, 248-255.
27. Sato, T. A., Kohama, T. & Sugiura, A. (1989). Protective role of human antibody to the fusion protein of measles virus. Microbiol Immunol 33, 601-607.
28. Sutcliffe, P. A. & Rea, E. (1996). Outbreak of measles in a highly vaccinated secondary school population. CMAJ 155, 1407-1413.
29. Tamin, A., Rota, P. A., Wang, Z.D., Heath, J. L., Anderson, L. J. & Bellini, W. J. (1994). Antigenic analysis of current wild type and vaccine strains of measles virus. J Infect Dis 170, 795-801.
30. + cytotoxic T cell clones. J Immunol 142, 2847-2854.
31. van den Hof, S., Berbers, G. A. M., de Melker, H. E. & Conyn-van Spaendonck, M. A. E. (1999). Sero-epidemiology of measles antibodies in the Netherlands, a cross-sectional study in a national sample and in communities with low vaccination coverage. Vaccine 18, 931-940.
32. WHO (2008). Progress in global measles control and mortality reduction, 2000-2007. Wkly Epidemiol Rec 83, 441-448.
33. Wiesmüller, K.-H., Spahn, G., Handtmann, D., Schneider, F., Jung, G. & Muller, C. P. (1992). Heterogeneity of linear B cell epitopes of the measles virus fusion protein reacting with late convalescent sera. J Gen Virol 73, 2211-2216.